Surveillance CT in patients with complete remission following curative chemoradiotherapy for Anal Cancer (Single Centre experience)

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter C. Mikropoulos
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors C. Mikropoulos1, J. Turner1, H. Lee1, G. Hegarty1, C. Bailey1, S. Houghton1, J. Summers2
  • 1Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom, /
  • 2Maidstone & Tunbridge Wells NHS Trust, Maidstone, United Kingdom, /

Abstract

In 2012 there were 1247 new cases in the UK (65% women and 35% men) and 307 deaths from anal cancer. Pattern of surveillance following radical chemoradiotherapy (CRT) treatment for Anal SqCC varies between oncology centres. Prior to January 2016 there was no international consensus on surveillance after treatment. The recently published National Comprehensive Cancer Network (NCCN) guidelines suggest annual imaging for 3 years for patients with locally advanced disease (T3/T4) or positive nodes (N+). We evaluated our experience of an alternative surveillance strategy adopted in our cancer network in patients treated between 2006 and 2013.